Value in health regional issues最新文献

{"title":"Association of Healthcare Fragmentation and the Survival of Patients with Colorectal Cancer in Colombia","authors":"Andrés Felipe Patiño-Benavidez MD ,&nbsp;Giancarlo Buitrago MD, MSc, PhD ,&nbsp;Nicolás Rozo-Agudelo MD ,&nbsp;Laura Estefanía Saldaña-Espinel MD ,&nbsp;Óscar Andrés Gamboa-Garay MD ,&nbsp;Javier Eslava-Schmalbach MD, MSc, PhD ,&nbsp;Carlos Bonilla-González MD ,&nbsp;Óscar Guevara-Cruz MD ,&nbsp;Rubén Ernesto Caycedo MD ,&nbsp;Edgar Germán Junca MD ,&nbsp;Ricardo Sánchez-Pedraza MD, MSc","doi":"10.1016/j.vhri.2023.12.003","DOIUrl":"https://doi.org/10.1016/j.vhri.2023.12.003","url":null,"abstract":"<div><h3>Objectives</h3><p>The objective of this study was to identify the association between healthcare fragmentation and survival for patients with colorectal cancer in Colombia.</p></div><div><h3>Methods</h3><p>A retrospective cohort study was performed using administrative databases, with an electronic algorithm to identify patients with colorectal cancer based on codes. The patients were enrolled between January 1, 2013, and December 31, 2016. The exposure variable was fragmentation, which was measured based on the number of different healthcare institutions that treated a patient during the first year after diagnosis. Matching was performed using propensity scores to control for confounding, and the hazard ratio for exposure to higher fragmentation was calculated for the matched sample.</p></div><div><h3>Results</h3><p>A total of 5036 patients with colorectal cancer were identified, 2525 (49.88%) of whom were women. The mean number of network healthcare institutions for the total sample was 5.71 (SD 1.98). The patients in the quartile with higher fragmentation had the highest mortality rate, 35.67 (95% CI 33.63-38.06) per 100 patients. The comparison of higher and lower quartiles of fragmentation resulted in an incidence rate ratio of 1.23 (95% CI 1.04-1.45; <em>P</em> = .02). Of the 5036 patients, 422 (8.38%) were classified as the exposed cohort (higher fragmentation). The total matched sample consisted of 844 subjects, and an HR of 1.26 (95%CI; 1.05-1.51) was estimated.</p></div><div><h3>Conclusions</h3><p>Exposure to more highly fragmented healthcare networks decreases overall 4-year survival for patients with colorectal cancer in Colombia.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2212109923001425/pdfft?md5=0839f20a8e3133bcfbd75fb3e288a1fa&pid=1-s2.0-S2212109923001425-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139493687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-Effectiveness Analysis Comparing QuantiFERON-TB Gold Plus Test and Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis Infection in Immunocompetent Subjects in Colombia","authors":"Cristian E. Navarro MD, MSc ,&nbsp;John E. Betancur MSc","doi":"10.1016/j.vhri.2023.11.010","DOIUrl":"https://doi.org/10.1016/j.vhri.2023.11.010","url":null,"abstract":"<div><h3>Objectives</h3><p><span>To determine the cost-effectiveness of the QuantiFERON-TB Gold Plus (QFT-Plus) test versus the tuberculin skin test in diagnosing </span>latent tuberculosis infection in immunocompetent subjects in the context of the Colombian healthcare system.</p></div><div><h3>Methods</h3><p>A hypothetical cohort of 2000 immunocompetent adults vaccinated with Bacillus Calmette-Guérin at birth<span> who are asymptomatic for tuberculosis disease was simulated and included in a decision tree over a horizon of &lt;1 year. The direct healthcare costs related to tests, antituberculosis treatment<span>, and medical care were considered, and diagnostic performance was used as a measure of effectiveness. The incremental cost-effectiveness ratio (ICER) was estimated, and univariate deterministic and probabilistic sensitivity analyses were carried out using 5000 simulations. The currency was the US dollar for the year 2022, with a cost-effectiveness threshold of $6666 USD (1 gross domestic product per capita for 2022).</span></span></p></div><div><h3>Results</h3><p>QFT-Plus was cost-effective with an ICER of $5687 USD for each correctly diagnosed case relative to a threshold of $6666 USD. In the deterministic analysis, QFT-Plus was cost-effective in half of the proposed scenarios. The variable that most affected the ICER was the prevalence of latent tuberculosis and test sensitivities. In the probabilistic analysis, QFT-Plus was cost-effective in 54.74% of the simulated scenarios, and tuberculin skin test was dominant in 13.84%.</p></div><div><h3>Conclusions</h3><p>The study provides evidence of the cost-effectiveness of QFT-Plus compared with the tuberculin skin test in diagnosing latent tuberculosis infection in immunocompetent adults in the Colombian context.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139493688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Shortfalls of Mental Health Compartment Models: A Call to Improve Mental Health Investment Cases in Developing Countries","authors":"Cyprian M. Mostert PhD ,&nbsp;Andrew Aballa MSc ,&nbsp;Linda Khakali MSc ,&nbsp;Willie Njoroge MSc ,&nbsp;Jasmit Shah PhD ,&nbsp;Samim Hasham PhD ,&nbsp;Zul Merali PhD ,&nbsp;Lukoye Atwoli PhD","doi":"10.1016/j.vhri.2023.11.012","DOIUrl":"https://doi.org/10.1016/j.vhri.2023.11.012","url":null,"abstract":"<div><h3>Objectives</h3><p>There are irregularities in investment cases generated by the Mental Health Compartment Model. We discuss these irregularities and highlight the costing techniques that may be introduced to improve mental health investment cases.</p></div><div><h3>Methods</h3><p>This analysis uses data from the World Bank, the World Health Organization Mental Health Compartment Model, the United Nations Development Program, the Kenya Ministry of Health, and Statistics from the Kenyan National Commission of Human Rights.</p></div><div><h3>Results</h3><p>We demonstrate that the Mental Health Compartment Model produces irrelevant outcomes that are not helpful for clinical settings. The model inflated the productivity gains generated from mental health investment. In some cases, the model underestimated the economic costs of mental health. Such limitation renders the investment cases poor in providing valuable intervention points from the perspectives of both the users and the providers.</p></div><div><h3>Conclusions</h3><p>There is a need for further calibration and validation of the investment case outcomes. The current estimated results cannot be used to guide service provision, research, and mental health programming comprehensively.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139487163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of Extent and Quality of Pharmacoeconomic Studies in India Using Quality of Health Economic Studies Score: A Targeted Literature Review","authors":"Neel Patel PharmD ,&nbsp;Samykya Yanamala MPT ,&nbsp;Mahendra Rai MPharm","doi":"10.1016/j.vhri.2023.11.013","DOIUrl":"https://doi.org/10.1016/j.vhri.2023.11.013","url":null,"abstract":"<div><h3>Objectives</h3><p>We assessed the quality of pharmacoeconomic studies conducted in India to report key areas of focus on the findings from the reviewed studies.</p></div><div><h3>Methods</h3><p>A targeted literature review was conducted using well-defined search strategy in PubMed to identify economic studies<span> conducted in India from May 2017 to April 2022. Only economic evaluation studies were included, whereas trial-based cost analyses were excluded. The quality of included studies was assessed using the Quality of Health Economic Studies tool, which comprised 16 evaluation criteria related to objectives, source, funding, perspective, subgroup analysis, scales, and economic modeling related parameters. Based on scores (100 points), studies were rated as good (≥75), fair (50-74), and poor (≤49) quality.</span></p></div><div><h3>Results</h3><p>Search strategy provided 888 studies; 95 of these were economic studies, and 74 were included in the analysis. These 74 studies included budget impact analysis (n = 4), burden of illness (n = 8), cost-benefit analysis (n = 5), cost-consequences analysis (n = 1), cost-effectiveness analysis (n = 55), and cost-utility analysis (n = 1). The average quality score of studies was 64.08. Of the studies, 15 studies were rated as “good,” 51 “fair,” and 8 “poor.” It was observed that primary outcome measures, stating negative outcomes, reporting bias, and implementing statistical and sensitivity analysis significantly affected the quality score.</p></div><div><h3>Conclusions</h3><p>Most of the health economic studies conducted in India are of fair quality, and there is a need for standardization of guidelines and increase in number of Indian peer-reviewed health economics journals. A collaborative effort from pharma companies, policy makers, education experts, curriculum planners, and medical faculty is needed to promote quality economic studies.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139487164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of Health-Related Quality of Life and Incurred Costs Among Human Immunodeficiency Virus, Tuberculosis, and Tuberculosis/HIV Coinfected Outpatients in Indonesia","authors":"Lusiana R. Idrus PhD ,&nbsp;Najmiatul Fitria PhD ,&nbsp;Fredrick D. Purba PhD ,&nbsp;Jan-Willem C. Alffenaar PhD, PharmD ,&nbsp;Maarten J. Postma PhD","doi":"10.1016/j.vhri.2023.10.010","DOIUrl":"https://doi.org/10.1016/j.vhri.2023.10.010","url":null,"abstract":"<div><h3>Objectives</h3><p>A growing interest in healthcare costs and patients’ health-related quality of life (HRQoL) exists in the context of the increasing importance of health technology assessment in countries with high numbers of the HIV and tuberculosis (TB) patient populations, such as Indonesia. This study aimed to analyze the HRQoL and out-of-pocket (OOP) costs of HIV, TB, and TB/HIV coinfected participants in a city in Indonesia with a high prevalence of HIV and TB.</p></div><div><h3>Methods</h3><p>A cross-sectional survey was conducted in the voluntary counseling and testing and lung clinics of Bekasi City Public Hospital (Indonesia) from January to March 2018. Patients’ HRQoL was measured using the EQ-5D-5L questionnaire, whereas OOP costs were extracted from a semistructured questionnaire.</p></div><div><h3>Results</h3><p>Of the 460 eligible participants, 82% resided in the city, 48% of them were married, and their median age was 34 years. Less than half were insured, and more than half had no source of income. The median values of health utilities for participants with HIV, TB, and TB/HIV were perceived as potentially high (1.0, 0.9, and 0.8, respectively). The TB/HIV coinfected outpatients had the highest OOP costs (US$94.5), with the largest contribution coming from direct medical OOP expenditures. Taking loans from family members was adopted as a financial strategy to overcome inadequate household incomes and high treatment costs.</p></div><div><h3>Conclusion</h3><p>This study suggests that TB/HIV coinfection potentially lowers HRQoL and increases healthcare costs and the need for economic analysis to underpin cost-effective treatment in such patients.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2212109923001292/pdfft?md5=432fbea61af0cff0fa19fdbdc0dcbcc8&pid=1-s2.0-S2212109923001292-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139399054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-effectiveness Analysis of Nivolumab Plus Ipilimumab Combination Therapy as First-line Treatment for Advanced Renal Cell Carcinoma in Japan","authors":"Tomomi Maeda BPharm ,&nbsp;Kensuke Moriwaki PhD ,&nbsp;Kosuke Morimoto MS ,&nbsp;Xiuting Mo PhD ,&nbsp;Takashi Yoshioka MD, PhD ,&nbsp;Rei Goto MD, PhD ,&nbsp;Kojiro Shimozuma MD, PhD","doi":"10.1016/j.vhri.2023.11.003","DOIUrl":"https://doi.org/10.1016/j.vhri.2023.11.003","url":null,"abstract":"<div><h3>Objectives</h3><p>The purpose of this study is to examine the cost-effectiveness of nivolumab (NIVO) plus ipilimumab (IPI) combination therapy (NIVO + IPI) compared with the sunitinib (SUN) therapy for Japanese patients with advanced renal cell carcinoma from the perspective of a Japanese health insurance payer.</p></div><div><h3>Methods</h3><p>A lifetime horizon was applied, and 2% per annum was set as the discount rate. The threshold was set as $ 75 000 per quality-adjusted life-year (QALY) gained. For the analytical method, we used a partitioned survival analysis model to estimate the incremental cost-effectiveness ratio (ICER), which is calculated by dividing incremental costs by incremental QALYs. Progression-free survival, progressive disease, and death were set as health states. Additionally, cost parameters and utility weights were set as key parameters. We set the intermediate/poor-risk population as the base case. Scenario analysis was conducted for the intention-to-treat population and the favorable risk population. Furthermore, one-way sensitivity analysis and probabilistic sensitivity analysis were conducted for each population.</p></div><div><h3>Results</h3><p>In the base-case analysis, the QALYs of NIVO + IPI and SUN were 4.32 and 2.99, respectively. NIVO + IPI conferred 1.34 additional QALYs. Meanwhile, the total costs in the NIVO + IPI and SUN were $692 288 and $475 481, respectively. As a result, the ICER of NIVO + IPI compared with SUN was estimated to be $162 243 per QALY gained. The parameter that greatly affected the ICER was the utility weight of progression-free survival in NIVO + IPI.</p></div><div><h3>Conclusions</h3><p>NIVO + IPI for advanced renal cell carcinoma seems to be not cost-effective compared with the SUN in the Japanese healthcare system.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2212109923001243/pdfft?md5=e553f9409f0e8fd85729dd65b18cba17&pid=1-s2.0-S2212109923001243-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139399141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-Effectiveness of Onasemnogene Abeparvovec Compared With Nusinersen and Risdiplam in Patients With Spinal Muscular Atrophy Type 1 in Brazil","authors":"Brígida Dias Fernandes PhD ,&nbsp;Fernanda D’Athayde Rodrigues PhD ,&nbsp;Hérica Núbia Cardoso Cirilo PhD ,&nbsp;Stéfani Sousa Borges MSc ,&nbsp;Bárbara Corrêa Krug MSc ,&nbsp;Livia Fernandes Probst PhD ,&nbsp;Ivan Zimmermann PhD","doi":"10.1016/j.vhri.2023.11.004","DOIUrl":"10.1016/j.vhri.2023.11.004","url":null,"abstract":"<div><h3>Objectives</h3><p>This study aimed to evaluate the cost-effectiveness of the onasemnogene abeparvovec in relation to nusinersen and risdiplam in the treatment of spinal muscular atrophy type 1 from the perspective of the Brazilian Unified Health System.</p></div><div><h3>Methods</h3><p>A Markov model was built on a lifetime horizon. Short-term data were obtained from clinical trials of the technologies and from published cohort survival curves (long term). Costs were measured in current 2022 local currency (R$) values and benefits in quality-adjusted life-years (QALYs). Utility values were derived from type 1 spinal muscular atrophy literature, whereas costs related to technologies and maintenance care in each health state were obtained from official sources of reimbursement in Brazil. Deterministic and probabilistic, as well as scenario, sensitivity analyses were performed.</p></div><div><h3>Results</h3><p>Compared with the less costly strategy (nusinersen), the use of onasemnogene abeparvovec resulted in an incremental cost of R$2.468.448,06 ($975 671.169 – purchasing power parity [PPP]) and a 3-QALY increment and incremental cost-effectiveness ratio of R$742.890,92 ($293 632.774 – PPP)/QALY. Risdiplam had an extended dominance from other strategies, resulting in an incremental cost-effectiveness ratio of R$926.586,22 ($366 239.612 – PPP)/QALY compared with nusinersen. Sensitivity analysis showed a significant impact of the follow-up time of the cohort and the cost of acquiring onasemnogene abeparvovec.</p></div><div><h3>Conclusions</h3><p>Over a lifetime horizon, onasemnogene abeparvovec seems to be a potentially more effective option than nusinersen and risdiplam, albeit with an incremental cost. Such a trade-off should be weighed in efficiency criteria during decision making and outcome monitoring from the perspective of the Brazilian Unified Health System.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139106746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multivariate Relationships Between Health Outcomes and Health System Performance Indicators: An Integrated Factor Analysis With Canonical Correlations","authors":"Yunus Emre Karatas MS ,&nbsp;Songul Cinaroglu PhD","doi":"10.1016/j.vhri.2023.10.009","DOIUrl":"10.1016/j.vhri.2023.10.009","url":null,"abstract":"<div><h3>Objectives</h3><p>This study aimed to investigate the relationships between sets of variables related to health system performance indicators and health outcomes.</p></div><div><h3>Methods</h3><p>The relationships between a set of health outcomes and a set of health system performance indicators of a developing country were examined using multivariate statistical analysis<span> techniques. A combinative strategy of explanatory factor analysis and the canonical correlation coefficient<span> was used to define linear structural relationships between study variables. Province-based data were gathered from2 official statistical records of the Turkish Statistical Institute for the year 2019. Life expectancy at birth, infant mortality rate, and crude death rate were accepted as health outcome indicators.</span></span></p></div><div><h3>Results</h3><p><span>The explanatory factor analysis indicated 2 independent variable groups, namely (1) health-related human resources and capacity and (2) health service utilization characteristics. The results of the canonical correlation analysis illustrated good performance to define sparse linear combinations of the 2 groups of variables. There existed strong positive correlations between health outcomes and health-related human resources and capacity indicators (r</span>_c = 0.83; <em>P</em> &lt; .001) and health service utilization indicators (r_c = 0.59; <em>P</em> &lt; .001).</p></div><div><h3>Conclusions</h3><p>The results of this study support the view that there is a linear and strong positive relationship between health outcomes and health-related human resources and capacity indicators. Further studies will combine big data analytics with multivariate statistical analysis techniques by studying large health system performance data sets.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139088750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Copyright/Subscription","authors":"","doi":"10.1016/S2212-1099(23)00136-X","DOIUrl":"https://doi.org/10.1016/S2212-1099(23)00136-X","url":null,"abstract":"","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S221210992300136X/pdfft?md5=82f8ebfe0024661b03cdf56a00c0010c&pid=1-s2.0-S221210992300136X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139433367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychometric Properties of the Persian Dizziness Handicap Inventory – Screening Version","authors":"Sadegh Jafarzadeh PhD ,&nbsp;Jamshid Jamali PhD","doi":"10.1016/j.vhri.2023.10.011","DOIUrl":"10.1016/j.vhri.2023.10.011","url":null,"abstract":"<div><h3>Objectives</h3><p><span>The Dizziness Handicap Inventory (DHI) is the most popular and widely used questionnaire in evaluating patients with </span>vertigo<span>. This questionnaire has a screening version with a high correlation with DHI. This study aimed to assess the psychometric properties of the Persian DHI – Screening version (DHI-S).</span></p></div><div><h3>Methods</h3><p><span><span>This cross-sectional and methodological study was conducted on 300 patients at the central vestibular clinic in Mashhad, Iran, from 2020 to 2021. First, the DHI-S was translated into Persian using the backward-forward translation method. Subsequently, the following types of validity and reliability were examined: content validity based on content validity index and content validity ratio, face validity based on impact score, construct validity based on </span>confirmatory factor analysis, internal consistency based on Cronbach’s α and Ω, and test-retest stability based on intraclass </span>correlation coefficient and smallest detectable change.</p></div><div><h3>Results</h3><p>The DHI-S had high content and face validity. Score 8 was selected for the cutoff point between patients and the normal group with a sensitivity of 63.67% and specificity of 96.08%. The construct validity indicated that the questionnaire is one-dimensional. The Cronbach’s α and Ω for internal consistency were 0.855 and 0.851, respectively. The intraclass correlation coefficient was 0.981 and the smallest detectable change was 5.521.</p></div><div><h3>Conclusions</h3><p>The DHI-S in the Persian language has high and acceptable psychometric properties. This questionnaire can be used in research and clinical settings.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2023-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139049420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}